Johnson & Johnson Total Liabilities 2010-2024 | JNJ
Johnson & Johnson total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
- Johnson & Johnson total liabilities for the quarter ending March 31, 2024 were $98.784B, a 10.66% decline year-over-year.
- Johnson & Johnson total liabilities for 2023 were $98.784B, a 10.66% decline from 2022.
- Johnson & Johnson total liabilities for 2022 were $110.574B, a 2.39% increase from 2021.
- Johnson & Johnson total liabilities for 2021 were $107.995B, a 3.24% decline from 2020.
Johnson & Johnson Annual Total Liabilities
(Millions of US $) |
| 2023 |
$98,784 |
| 2022 |
$110,574 |
| 2021 |
$107,995 |
| 2020 |
$111,616 |
| 2019 |
$98,257 |
| 2018 |
$93,202 |
| 2017 |
$97,143 |
| 2016 |
$70,790 |
| 2015 |
$62,261 |
| 2014 |
$60,606 |
| 2013 |
$58,630 |
| 2012 |
$56,521 |
| 2011 |
$56,564 |
| 2010 |
$46,329 |
| 2009 |
$44,094 |
Johnson & Johnson Quarterly Total Liabilities
(Millions of US $) |
| 2023-12-31 |
$98,784 |
| 2023-09-30 |
$94,833 |
| 2023-06-30 |
$115,277 |
| 2023-03-31 |
$125,100 |
| 2022-12-31 |
$110,574 |
| 2022-09-30 |
$100,525 |
| 2022-06-30 |
$101,367 |
| 2022-03-31 |
$103,646 |
| 2021-12-31 |
$107,995 |
| 2021-09-30 |
$108,956 |
| 2021-06-30 |
$106,860 |
| 2021-03-31 |
$106,723 |
| 2020-12-31 |
$111,616 |
| 2020-09-30 |
$106,220 |
| 2020-06-30 |
$95,402 |
| 2020-03-31 |
$93,723 |
| 2019-12-31 |
$98,257 |
| 2019-09-30 |
$97,311 |
| 2019-06-30 |
$94,332 |
| 2019-03-31 |
$91,072 |
| 2018-12-31 |
$93,202 |
| 2018-09-30 |
$91,077 |
| 2018-06-30 |
$92,476 |
| 2018-03-31 |
$93,370 |
| 2017-12-31 |
$97,143 |
| 2017-09-30 |
$81,679 |
| 2017-06-30 |
$80,885 |
| 2017-03-31 |
$74,577 |
| 2016-12-31 |
$70,790 |
| 2016-09-30 |
$67,600 |
| 2016-06-30 |
$67,341 |
| 2016-03-31 |
$63,584 |
| 2015-12-31 |
$62,261 |
| 2015-09-30 |
$61,712 |
| 2015-06-30 |
$60,905 |
| 2015-03-31 |
$60,712 |
| 2014-12-31 |
$60,606 |
| 2014-09-30 |
$55,506 |
| 2014-06-30 |
$57,152 |
| 2014-03-31 |
$56,748 |
| 2013-12-31 |
$58,630 |
| 2013-09-30 |
$57,129 |
| 2013-06-30 |
$54,660 |
| 2013-03-31 |
$54,681 |
| 2012-12-31 |
$56,521 |
| 2012-09-30 |
$55,190 |
| 2012-06-30 |
$55,316 |
| 2012-03-31 |
$54,828 |
| 2011-12-31 |
$56,564 |
| 2011-09-30 |
$50,294 |
| 2011-06-30 |
$49,982 |
| 2011-03-31 |
$48,287 |
| 2010-12-31 |
$46,329 |
| 2010-09-30 |
$40,956 |
| 2010-06-30 |
$39,449 |
| 2010-03-31 |
$40,527 |
| 2009-12-31 |
$44,094 |
| 2009-09-30 |
$41,174 |
| 2009-06-30 |
$41,191 |
| 2009-03-31 |
$42,309 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$348.864B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
